Alexion Stock Analysis: New Management Will Lead ALXN in a Prosperous Direction
This article was written by Jason Schwartz, a Financial Analyst at I Know First,
Alexion Stock Analysis
Summary
- Alexion is best known for the development of Soliris
- Used to treat patients with PNH and aHUS, both rare medical conditions.
- Internal investigation results in overhaul of senior management including CEO and CFO
- Bullish I Know First Forecast for AXLN